Critical Survey: Motus GI (NASDAQ:MOTS) versus GBS (NYSE:GBS)

Volatility and Risk

Motus GI has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Institutional & Insider Ownership

20.1% of Motus GI shares are held by institutional investors. Comparatively, 2.8% of GBS shares are held by institutional investors. 0.3% of Motus GI shares are held by insiders. Comparatively, 0.3% of GBS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Motus GI and GBS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Motus GI	N/A	N/A	N/A
GBS	N/A	-85.64%	-54.42%

Valuation and Earnings

This table compares Motus GI and GBS”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Motus GI	$319,000.00	0.00	-$12.87 million	($15.64)	N/A
GBS	N/A	N/A	-$8.31 million	($0.56)	-3.04

GBS has lower revenue, but higher earnings than Motus GI. GBS is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.

Summary

Motus GI beats GBS on 6 of the 9 factors compared between the two stocks.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

About GBS

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.